Cube Dx molecular pathogen tests support microbiologists and infectious disease specialist in providing early indications of sepsis-causing pathogens in whole blood. As no microbiological culturing is necessary, time to result reduces tremendously.
This is particularly relevant for microorganisms that have been weakened by antimicrobial treatment or which demonstrate slow growth in or on microbiological nutrient media. The broad spectrum of the Cube Dx tests is ideally suited to test for pathogens causing sepsis and other severe infections.
For such kind of testing a high number of negative results is expected. Therefore it must be ensured that negative results are due to negative samples and not caused by flaws in the process. Therefore we offer a stringent process control that undergoes the same procedures as the sample itself – including pathogen enrichment and DNA extraction.
Cube Dx' Internal Process Control (IPC) consists of frozen bacterial material that is dissolved within the sample. Both qPCR (during the amplification process) and probes on the hybcell (during the identification process) finally confirm the presence of the IPC.
PCR-Boxes: Bacteria (16S) / Fungi (28S) / Resistance
Detection of bacterial 16S / fungal 28S / resistance genes using (q)PCR device
12x 20µL mastermix
hybcell Bacteria / Fungi / Pathogens DNA
Multiplex DNA-test of bacterial and fungal targets
IPC and PCR-Box IPC
Frozen solution of bacterial cells put into sample and PCR-mastermix for amplification of these cells
25x 20 µL IPC and 12x 20µL mastermix
Mailing list subscription
Our new device - hyborg Dx RED2 - is now labelled CE-IVD. First devices are tested at customer sites.
Meet us next...
at MISK Global Forum in Riyadh, Saudi Arabia (12-14 November, 2019).
at DxPx Conference in Duesseldorf, Germany (18 November, 2019).
at ECCMID in Paris, France (18-21 April, 2019).
Cube Dx GmbH | Westbahnstrasse 55 | 4300 St. Valentin (Austria) | E-Mail: firstname.lastname@example.org
The development of Cube Dx' products has been supported under the H2020 funding scheme.